Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10662571 | 0.84 | KDM4E (0.67) | KDM4EALDH1A1L3MBTL1GAARAB9A | |
| SCHEMBL11133373 | 0.83 | KDM4E (0.51) | HTTKDM4EALDH1A1L3MBTL1GAA | |
| SCHEMBL457214 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1L3MBTL1GAARAB9A | |
| SCHEMBL28117084 | 0.81 | MAPT (0.50) | HTTKDM4EALDH1A1GAAMEN1 | |
| SCHEMBL1233566 | 0.81 | SMN1; SMN2 (0.53) | HTTALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL1887021 | 0.81 | MAPT (0.67) | HTTKDM4EALDH1A1GAARAB9A | |
| SCHEMBL4164719 | 0.81 | MAPT (0.47) | HTTKDM4EALDH1A1L3MBTL1MEN1 | |
| SCHEMBL14031287 | 0.79 | KDM4E (0.57) | KDM4EALDH1A1L3MBTL1GAARAB9A | |
| SCHEMBL21995716 | 0.79 | ALDH1A1 (0.41) | HTTALDH1A1GAAKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27528526 | 0.79 | SMN1; SMN2 (0.51) | HTTALDH1A1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118619952-A | Aloperine derivative, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-09-10 | — | — | CN | disclosed |
| US-20230263167-A1 | METHOD OF PREPARING A BISMUTH SULFIDE PARTICLE CONTAINING ANTIBACTERIAL COMPOSITION | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-08-24 | — | — | US | disclosed |
| US-11700855-B2 | Method for preventing or reducing growth of a microorganism on a surface | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-07-18 | — | — | US | disclosed |
| CN-108369222-B | Opioid receptor modulators and uses thereof | 明尼苏达大学董事会 | 2021-06-04 | — | — | CN | disclosed |
| US-20210061670-A1 | METHOD FOR PREVENTING OR REDUCING GROWTH OF A MICROORGANISM ON A SURFACE | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2021-03-04 | — | — | US | disclosed |
| US-10934176-B2 | Methods of degrading organic pollutants and preventing or treating microbe using Bi2S3-CdS particles | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2021-03-02 | — | — | US | disclosed |
| EP-3344997-B1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | UNIV MINNESOTA (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3344997-B1 | OPIOID RECEPTOR MODULATORS AND USE THEREOF | UNIV MINNESOTA (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200102228-A1 | METHODS OF DEGRADING ORGANIC POLLUTANTS AND PREVENTING OR TREATING MICROBE USING Bi2S3-CdS PARTICLES | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2020-04-02 | — | — | US | disclosed |
| US-10105687-B1 | Heterostructured Bi2S3—ZnS photocatalysts and methods thereof | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2018-10-23 | — | — | US | disclosed |
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1152759-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | disclosed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000047194-A9 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | DIMENSIONAL PHARM INC (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1054886-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000047194-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-1999040088-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | C1S, C1R, C9 | HTT 913/4885KDM4E 4740/4885ALDH1A1 3467/4885 |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | HTT 2551/4885KDM4E 3095/4885ALDH1A1 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.